摘要
目的评价肝动脉化疗栓塞联合索拉非尼治疗中国中晚期原发性肝细胞癌的治疗效果。方法通过计算机检索知网数据库、万方数据库、PubMed数据库、Google Scholar、Springer Linke等数据库,截止至2018年6月发表的有关TACE联合索拉非尼为观察组与单用TACE治疗中国中晚期原发性肝细胞癌的对照试验。对符合纳入标准的文献进行资料提取和质量评价,采用Rev Man5.0软件统计。结果本荟萃分析共纳入10篇研究涉及802例中国中晚期原发性肝细胞癌患者。结果表明,TACE联合索拉非尼明显提高了患者的短期和长期生存情况。短期生存情况为治疗前后疾病控制率(OR 3.28,P=0.0006),3个月后疾病控制率(OR 2.29,P=0.01),6个月后疾病控制率(OR3.67,P=0.007)。长期生存率包括6个月生存率(OR 2.66,P=0.001),1年生存期率(OR 3.31,P <0.00001),3年生存率(OR 4.33,P=0.0002),5年生存率(OR 3.28,P=0.003)均较高。结论对于中国中晚期原发性肝细胞癌患者,TACE联合索拉非尼治疗在短期疗效和长期生存上,都优于单一TACE治疗,但由于本文纳入研究数量相对较少且文献质量较低,可能影响结果的可信度。因此,还需要大样本、多中心的随机对照试验及长期随访来进一步证实。
Objective To evaluate the effects of TACE(Transcatheter Arterial Chemoembolization)combined with Sorafenib in the treatment of the intermediate and advanced primary hepatocellular carcinoma in China.Methods Related articles were referred to in this paper,including the ones about the treatment of intermediate and advanced primary hepatocellular carcinoma with TACE(Transcatheter Arterial Chemoembolization)combined with Sorafenib and only TACE in China which were published as of June 2018 and searched in CNKI,Wanfang,PubMed,Google Scholar,Springer Linke and other databases.Among the cases in these articles,those who were treated with TACE combined with Sorafenib consisted of an observation group while those who were treated with only TACE consisted of a control group.Data extraction and quality assessment were conducted for qualified articles,and the software RevMan 5.0 was used for statistics.Results This meta-analysis involved a total of 10 study articles and 802 cases of primary intermediate and advanced hepatocellular carcinoma in China.The results showed that TACE combined with Sorafenib significantly improved short-and long-term survival of the patients.Short-term survival included the DCR(disease control rate)before and after treatment(OR 3.28,P=0.0006),DCR after three months(OR 2.29,P=0.01)and DCR after six months(OR 3.67,P=0.007).Long-term survival included a six-month survival rate(OR 2.66,P=0.001),one-year survival rate(OR 3.31,P<0.00001),three-year survival rate(OR 4.33,P=0.0002)and five-year survival rate(OR3.28,P=0.003).Conclusion For the treatment of primary intermediate and advanced primary hepatocellular carcinoma in China,TACE combined with Sorafenib is superior to single TACE in short-term effectiveness and long-term survival.However,the relatively small number of studies included in this analysis and the low quality of the articles may affect the credibility of the results.Therefore,large-sample and multi-center randomized clinical trials and long-term followup are required to further confirm the rusults.
作者
赵燕珍
刘丽敏
朱斌
ZHAO Yan-zhen;LIU Li-min;ZHU Bin(The First Affiliated Hospital of Xinxiang Medical College,Xinxiang,Henan 453000)
出处
《智慧健康》
2019年第15期90-93,共4页
Smart Healthcare